 Connection
Ronald Vagnozzi to Cardiomyopathies
This is a "connection" page, showing publications Ronald Vagnozzi has written about Cardiomyopathies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.802 |
|
|
|
-
Vagnozzi RJ, Johansen AKZ, Molkentin JD. CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart. Mol Ther. 2019 11 06; 27(11):1869-1871.
Score: 0.483
-
Baldwin TA, Teuber JP, Kuwabara Y, Subramani A, Lin SJ, Kanisicak O, Vagnozzi RJ, Zhang W, Brody MJ, Molkentin JD. Palmitoylation-dependent regulation of cardiomyocyte Rac1 signaling activity and minor effects on cardiac hypertrophy. J Biol Chem. 2023 12; 299(12):105426.
Score: 0.160
-
Bowers SLK, Meng Q, Kuwabara Y, Huo J, Minerath R, York AJ, Sargent MA, Prasad V, Saviola AJ, Galindo DC, Hansen KC, Vagnozzi RJ, Yutzey KE, Molkentin JD. Col1a2-Deleted Mice Have Defective Type I Collagen and Secondary Reactive Cardiac Fibrosis with Altered Hypertrophic Dynamics. Cells. 2023 08 30; 12(17).
Score: 0.158
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|